Retreatment decisions for bovine respiratory disease (BRD) are often made when animals fail to rebound as quickly as expected. A calf still looks depressed, a temperature remains elevated, or animal handlers question whether the initial therapy worked. In those moments, retreatment can feel like the safest option, but evidence suggests when cattle are eligible for retreatment can be just as important as what antimicrobials are used.
Post-treatment interval (PTI) refers to the amount of time that should pass after antimicrobial administration before an animal is eligible for another treatment. It’s not about delaying care arbitrarily, but about allowing drugs time to do what they are designed to do before concluding that further intervention is required.
“We have very high-quality medications and sometimes we need to let those drugs have enough time to work,” explains Dr. D.L. Step, senior professional services veterinarian at Boehringer Ingelheim. “By allowing that period of time, we don’t have to stress the animals by getting them up into a chute to be further evaluated for more treatment.”
PTI is a Clinical Decision
PTI is a question of timing. Once an animal meets a BRD case definition and receives antimicrobial therapy, clinicians must decide how long to wait before reassessing and potentially retreating. That decision is often influenced by clinical appearance and management pressure rather than pharmacologic behavior.
This raises the question: If retreatment happens too soon, are cattle actually failing therapy, or are they still in the expected window of recovery?
To examine that question, a 2020 field study evaluated PTIs following treatment with gamithromycin in cattle with naturally occurring BRD. Animals were assigned to retreatment eligibility at three, six, nine or 12 days.
The results revealed a clear pattern. Cattle eligible for retreatment at three days had higher retreatment rates. At the opposite extreme, cattle held to a 12-day PTI experienced poorer final outcomes, including higher case fatalities. The most favorable outcomes in this study occurred when retreatment eligibility fell between six and nine days.
These results suggest there is both a lower and an upper boundary for effective PTI, at least for gamithromycin.
These results are grounded in how gamithromycin behaves in the animal.
“Gamithromycin can stay in alveolar macrophages that fight infection down in the lung,” Step says. “We know the drug can stay there for up to 10 days.”
This persistence provides a biologic explanation for the observed outcomes. Retreatment at three days may occur before the drug has completed its therapeutic effect. Extending PTI too long, however, may delay intervention in animals that need further evaluation, which may explain the different outcomes at 12 days.
Handling stress may also be a contributing factor. Earlier retreatment requires pulling recovering cattle back through the chute, which may further compromise recovery.
When PTI did not change outcomes
Not all antimicrobials behave the same way. A more recent multisite study from Kansas State University evaluated PTIs following pradofloxacin treatment for BRD in stocker cattle. In that work, cattle were assigned to retreatment eligibility at three, six or nine days and followed for 45 days.
Within this range, no statistically significant differences were detected in the first treatment success, case fatality or days to death among PTI groups. Unlike the gamithromycin study, PTIs beyond nine days were not evaluated, so the effect of extended intervals could not be assessed.
The pradofloxacin findings reinforce an important point: PTI effects are drug-specific. These results do not mean that PTI timing is irrelevant, rather that no effect was detected under the conditions of this study.
PTI and Antimicrobial Stewardship
PTI is a stewardship issue grounded in outcomes, not restriction. In the gamithromycin study, shorter PTIs resulted in more antimicrobial use without improved performance. Allowing appropriate time between treatments reduced retreatment frequency and improved outcomes.
“If you wait a little bit longer, the outcomes are better and you don’t use as many drugs,” Step says.
This approach aligns stewardship with clinical effectiveness rather than limiting access to therapy.
What this Means for BRD Protocols
The practical takeaway is not a single retreatment day, but rather the opportunity for a retreatment window that reflects drug characteristics, cattle type and management conditions.
“A veterinarian can prescribe and say, ‘Maybe we wait seven or eight or nine days,’” Step says.
PTI should be considered alongside antimicrobial selection and case definition rigor.
By evaluating each case in context and adjusting protocols based on observed outcomes, PTI deserves the same level of attention as any other component of BRD treatment decision-making.
